Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: E'Lane who wrote (11998)	7/23/1998 1:17:00 AM
From: Jim	Respond to of 23519

I hear there is some type of deal in the works that would split up VVUS in 2 parts, with VVUS selling the rights to there pill to [Astra??] for $12.00,and the both working on future sales of MUSE in the present form. Total price is about 18.00 to share holders. This info is not confirmed, but comes from a very good source If you read between the lines, this deal sounds like its right on the money 1. VVUS needs a partner 2. VVUS needs $$$$ 3.VVUS needs time 4. Sales outside US are growing rapidly 5. The PILL COULD BLOW AWAY VIAGRA [LESS SIDE AFFECTS] 6.VVUS remains a public co. with a strong future

To: E'Lane who wrote (11998)	7/23/1998 1:41:00 AM
From: martin killoran	Read Replies (1) \| Respond to of 23519

e'lane ...it's been a fun day

To: E'Lane who wrote (11998)	7/23/1998 9:00:00 AM
From: E'Lane	Read Replies (3) \| Respond to of 23519

GOOD MORNING ALL!!! Beautiful day here...hope it is for you too! One more time for good measure! **************************** Vivus Says Only 1 Patient Died After Using Impotence Treatment Mountain View, California, July 22 (Bloomberg) -- Vivus Inc. said it knows of only one death among the 600,000 patients who have used its Muse impotence treatment, following reports that 39 men have died after taking Pfizer Inc.'s blockbuster drug Viagra. Mountain View, California-based Vivus made the comment a day after the U.S. Food and Drug Administration updated its Web site with safety information on Viagra, disclosing the 39 deaths and saying it hasn't changed its view that the Pfizer drug is safe. ''Muse does not appear to pose additional risk to the man with cardiovascular disease,'' said Vivus Vice President Neil Gesundheit. ''This data is meant to be put into contradistinction to what's on the FDA Web site for Viagra.'' Sales of Muse, a pellet that's injected into the urethra, have tumbled since easier-to-take Viagra was introduced in April, quickly dominating the market for impotence treatments. Vivus blamed a second-quarter loss of $17.7 million on competition from Pfizer's drug and earlier this month said it will eliminate its sales force because it can no longer afford to market Muse on its own. Of the 39 Viagra users who died, 24 suffered some kind of heart problem, 13 died from unknown or unconfirmed causes and two had strokes, the FDA said. At least six of them took Viagra along with a heart medication known to have a dangerous interaction with Viagra that Pfizer and the FDA have warned doctors about. Since April, some 3 million Viagra prescriptions have been filled for about 2 million men, according to Pfizer. Vivus rose 1/2 to 7 9/16. Pfizer rose 2 1/4 to 116 3/8. 20:04:17 07/22/1998 Any redistribution of Bloomberg content, including by framing or similiar means, is expressly prohibited without the prior written consent of Bloomberg L.P. Any reference to the material must be properly attributed to Bloomberg News. The information herein was obtained from sources which Bloomberg L.P. and its suppliers believe reliable, but they do not guarantee its accuracy. Neither the information, nor any opinion expressed, constitutes a solicitation of the purchase or sale of any securities or commodities.(C) Copyright 1998 Bloomberg L.P. BLOOMBERG, Bloomberg News, Bloomberg Financial Markets, Bloomberg Television, Bloomberg News Radio are trademarks, tradenames and service marks of Bloomberg L.P.